Physician profile
Thomas Toothaker
NPI 1477705382
$2,577.18
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,511 · 2023: $44.56 · 2024: $21.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $282.56 | 2019 | |
| Biogen, INC. | $280.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $193.32 | 2019 | |
| Alexion Pharmaceuticals, INC. | $168.80 | 2019 | |
| Genzyme Corporation | $150.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $148.42 | 2019 | |
| Emd Serono, INC. | $147.05 | 2019 | |
| Assertio Therapeutics, INC. | $100.79 | 2019 | |
| Allergan, INC. | $95.61 | 2019 | |
| Csl Behring | $82.60 | 2019 | |
| Adamas Pharmaceuticals, INC. | $80.42 | 2019 | |
| Acorda Therapeutics, INC | $77.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $74.97 | 2019 | |
| Acadia Pharmaceuticals INC | $69.46 | 2019 | |
| Abbvie INC. | $66.00 | 2023-2024 | Qulipta, Botox |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $58.84 | 2019 | |
| Amgen INC. | $58.73 | 2019 | |
| Lilly USA, LLC | $55.10 | 2019 | |
| Genentech USA, INC. | $53.52 | 2019 | |
| Merz North America, INC. | $53.38 | 2019 | |
| Vertical Pharmaceuticals, LLC | $31.62 | 2019 | |
| Promius Pharma LLC | $31.35 | 2019 | |
| Mallinckrodt Enterprises LLC | $28.51 | 2019 | |
| Grifols USA, LLC | $23.98 | 2019 | |
| Neurocrine Biosciences, INC. | $21.29 | 2019 | |
| Akcea Therapeutics, INC. | $20.71 | 2019 | |
| Ge Healthcare | $19.45 | 2019 | |
| Greenwich Biosciences, INC. | $18.15 | 2019 | |
| Bausch Health US, LLC | $14.91 | 2019 | |
| Mdd US Operations, LLC | $14.72 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.36 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.06 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Toothaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.